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Abstract
Background: The presence of the tetraspanins CD9, CD63, CD81 and CD82 at HIV-1 budding
sites, at the virological synapse (VS), and their enrichment in HIV-1 virions has been well-
documented, but it remained unclear if these proteins play a role in the late phase of the viral
replication cycle. Here we used overexpression and knockdown approaches to address this
question.
Results: Neither ablation of CD9, CD63 and/or CD81, nor overexpression of these tetraspanins
was found to affect the efficiency of virus release. However, confirming recently reported data,
tetraspanin overexpression in virus-producing cells resulted in the release of virions with
substantially reduced infectivity. We also investigated the roles of these tetraspanins in cell-to-cell
transmission of HIV-1. Overexpression of CD9 and CD63 led to reduced cell-to-cell transmission
of this virus. Interestingly, in knockdown experiments we found that ablation of CD63, CD9 and/
or CD81 had no effect on cell-free infectivity. However, knockdown of CD81, but not CD9 and
CD63, enhanced productive particle transmission to target cells, suggesting additional roles for
tetraspanins in the transmission process. Finally, tetraspanins were found to be downregulated in
HIV-1-infected T lymphocytes, suggesting that HIV-1 modulates the levels of these proteins in
order to maximize the efficiency of its transmission within the host.
Conclusion: Altogether, these results establish an active role of tetraspanins in HIV-1 producer
cells.
Background
Persistence of HIV-1 in infected individuals is a major
public health problem. Despite great advances in anti-ret-
roviral therapies, the virus cannot be completely elimi-
nated once infection is established. One (of the many)
potential explanation(s) for this failure of infected indi-
viduals to clear the virus is that its mode of spread does
not allow components of the immune system to recognize
and attack it appropriately. It is now well documented
that HIV-1 can be transferred very efficiently from cell-to-
cell, most likely upon induction of so-called virological
synapses (VSs), sites of transient adhesion between
infected (producer) and uninfected (target) cells [1-7].
Upon formation of the VS, viral budding is polarized
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towards the target cell, and the virus is thought to be
released into the tight synaptic cleft where it appears to be
at least partially protected from neutralizing antibodies
[3].
Clearly, how the VS is formed and organized is an impor-
tant question. Like immunological synapse (IS) forma-
tion, VS formation likely requires the concerted action of
numerous cellular factors, several of which are also uti-
lized for IS formation. Indeed it has been proposed that
HIV-1 infection, followed by the expression of viral pro-
teins, favors the formation of VSs at the expense of IS for-
mation (e.g. [8], reviewed in [9]). However, we are only at
a very early stage of understanding the relative distribu-
tion and function of viral and cellular elements during the
formation, maintenance and disengagement of the VS.
Specifically, while some studies show that VS formation
and virus transfer is primarily driven by Env-CD4 interac-
tions [2,3,10], other cellular components involved are
only beginning to be unveiled.
Tetraspanins are a 33-member family of 4-span trans-
membrane proteins. They are thought to act as membrane
organizers, selectively clustering proteins into microdo-
mains in order for specific membrane-based processes to
proceed [11,12]. These processes include (among others)
cell-cell fusion, cell adhesion, and cell motility (reviewed
e.g. in [13,14]). Interestingly, tetraspanins are recruited to
sites of HIV-1 budding, as evidenced by their incorpora-
tion into viral particles [15,16], as well as their clustering
at budding sites in virus-producing cells, including the VS
[17-22]. While several reports document involvement of
these proteins in HIV-1 entry and possibly activation of
newly infected cells [23-27], it remained unclear whether
these proteins also play a functional role during the late
stages of virus replication, specifically during the budding
process [28-30]. We have recently shown that treatment of
virus-producing HeLa cells with an anti-CD9 antibody
reduces virus release [31]. While this pointed towards a
potential role of this tetraspanin in HIV-1 budding, it
appears now more likely that this treatment, which results
in the clustering not only of CD9 but also of other tet-
raspanins and of all the viral structural components, sim-
ply redirects particle formation towards cell-cell contact
sites, thus reducing the overall area through which prog-
eny virus can exit from cells [32].
Here, we show that tetraspanins in producer cells, rather
than acting as budding co-factors, regulate cell-free virus
infectivity (confirming recent data by the Koyanagi labo-
ratory [33]) and cell-to-cell transmission. Further, we pro-
vide evidence that HIV-1 modulates the levels of
tetraspanins in producer cells in order to maximize the
efficiency of its dissemination. Altogether, our findings
identify new cellular players involved in the late stages of
viral replication, specifically in the transfer of viral parti-
cles from cell-to-cell, a process that is crucial for HIV-1 dis-
semination in infected individuals.
Methods
Cell culture, plasmids, and antibodies
The following reagents were obtained through the NIH
AIDS Research and Reference Reagent Program, Division
of AIDS, NIAID, NIH: TZM-bl cells from Dr. John C. Kap-
pes, Dr. Xiaoyun Wu and Tranzyme Inc, Jurkat Clone E6-
1 cells from Dr. Arthur Weiss, CEM.NKR-CCR5-Luc
(referred to as CEM-Luc throughout) cells from Drs. John
Moore and Catherine Spenlehauer, CEM-GFP cells from
Dr. Jacques Corbeil; as well as reverse transcriptase inhib-
itors Zidovudine and Efavirenz, and the following anti-
bodies: monoclonal antibody to HIV-1 p24 (AG3.0) from
Dr. Jonathan Allan, HIVIG from NABI and NHLBI, HIV-1
p24 Hybridoma (183-H12-5C) from Dr. Bruce Chesebro.
HeLa and TZM-bl cells were maintained in DMEM with
10% FBS. All T cell lines were maintained in RPMI with
10% FBS. Media for CEM-GFP and CEM.NKR-CCR5-Luc
were supplemented with 0.5 and 0.8 mg/ml G418, respec-
tively.
The following proviral plasmids were used: pNL4-3,
pNL4-3deltaNef (provided by Dr. John Guatelli, UCSD),
HIV-i-GFP (pNL4-3 containing a MA-GFP fusion, and an
additional protease cleavage site between MA and GFP)
[34], and HXB2 (provided by Dr. Clarisse Berlioz-Torrent,
Institut Cochin, France). Previously described [33], tet-
raspanin and L6 expression plasmids (in pCMV-Sport6
vector) were provided by Dr. Koyanagi, (Kyoto University,
Japan). The FG12 shRNA delivery vector system was
developed in Dr. David Baltimore's laboratory [35] and
was obtained via the AddGene service (addgene.org).
Tetraspanin knockdown
ShRNA sequences were based on previously described
siRNA sequences: [24] for CD9 and CD81, and Ambion's
pre-designed CD63 (ID:10412). The scrambled shRNA
sequence was generated by randomly scrambling the
siRNA sequence used for CD63 silencing. Using NCBI
BLAST, the scrambled sequence showed no significant
homology with the human genome.
The lentiviral shRNA system used has been previously
described [35], and cloning and other procedures were
carried out essentially as described. Briefly, stock lentivi-
ruses were produced by transfecting 293T cells with the
FG12shRNA plasmids, pVSVG and packaging plasmid
pDeltaR8.2. Supernatants were concentrated 200 fold by
centrifugation at 50,000 g for 2 hours, then stored at -
80°C. Titer was determined by infecting either HeLa or
Jurkat cells with serial dilutions of virus, then determiningRetrovirology 2009, 6:64 http://www.retrovirology.com/content/6/1/64
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%GFP positive cells by flow cytometry. Infections were
done in the presence of 8 μg/ml polybrene (HeLa) or 10
μg/ml DEAE-dextran (Jurkat) to enhance transduction
efficiency. Knockdown efficiency was confirmed by West-
ern blot and flow cytometry, using the following antibod-
ies: mouse anti-CD63, clone H5C6 (Developmental
Studies Hybridoma Bank at the University of Iowa),
mouse anti-CD9, clone K41 (Bachem), mouse anti-CD81,
clone JS-81 (BD Biosciences), and mouse anti-GAPDH
(Abcam). GAPDH was used as a loading control. Lysates
were analyzed for protein content using the Coomassie
Plus reagent (Pierce), and equal amounts of protein (5–10
μg) were loaded for each lane.
HIV-1 release assays
HeLa cells were seeded at a density of 0.3 × 106 cells per
well in 6 well plates (day 0). On day 1, cells were trans-
duced with lentiviruses carrying shRNA at MOI = 8 over-
night in the presence of 8 μg/ml Polybrene (Sigma). On
day 3, cells were transfected with pNL4-3, using
Lipofectamine2000 following manufacturer's instructions
(Invitrogen). On day 5, supernatant containing released
virus was centrifuged at 3,000 g, 10 minutes, to pre-clear,
followed by 2 hours at 16,000 g through a 20% sucrose
cushion. Viral pellets were re-suspended in TNE lysis
buffer (10 mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA,
1% Triton-X100). Cells were lysed, centrifuged at 16,000
g for 10 minutes and were loaded for SDS-PAGE and
Western blot together with released virus. AG3.0 anti-p24
antibody was used to detect Gag. Cell lysates and superna-
tants were also analyzed for p24 content by p24 antigen
capture ELISA as described [36], with the following mod-
ifications: HIV-IG was used as an antigen detection anti-
body, followed by donkey anti-human HRP-conjugated
antibody (Jackson ImmunoResearch) and a TMB sub-
strate kit was used for colorimetric detection (Pierce).
Cell-free infectivity assay
Supernatants from virus-expressing HeLa cells were pre-
cleared at 3,200 g for 10 minutes, then assayed for p24
content using a home-made ELISA kit (see above). TZM-
bl reporter cells, which express beta-galactosidase and
luciferase under the control of the HIV LTR, were plated in
96-well plates (10,000 cells/well) one day prior to infec-
tion. 0.2 – 0.05 ng of p24 in 100 μl of media containing
20 μg/ml DEAE-dextran (to enhance infection) was used
per well. 48 hours later, media was removed, cells were
washed and 50 μl/well of All-in-One mammalian beta-
galactosidase reagent (Pierce, USA) was added. The plate
was incubated at 37°C for 5–30 minutes, and absorbance
was read at 405 nm in a microplate reader. The absorb-
ance was normalized by the p24 input for different dilu-
tions and further normalized to the mock condition for
that experiment (set to 1).
Cell-to-cell transmission assay
Co-transfections
50,000 HeLa cells/well were plated in 24 well plates on
Day 0. On Day 1, cells were co-transfected with tet-
raspanin expression plasmids and the appropriate provi-
ral plasmid at 1:2 ratio. Transfections were performed in
quadruplicate. On Day 2, media was removed, and target
cells (either 0.2 million (mio) CEM-GFP or 0.4 mio CEM-
Luc cells) were added to 2 out of the 4 quadruplicate
wells. On Day 3, non-adherent target cells were removed
and transferred to a new plate. Supernatants from repli-
cate wells without target cells were harvested and assayed
for p24 content using a home-made ELISA kit (used for
normalization, see below). These supernatants were also
used in infectivity assays (see above). On Day 4, non-
adherent target cells were removed from the second plate.
CEM-GFP cells were fixed with 4% paraformaldehyde
(PFA) and analyzed by flow cytometry, the readout being
%GFP positive cells. CEM-Luc cells were lysed in TNE
Lysis buffer, then assayed for luciferase activity using the
Bright-Glo Luciferase Assay System (Promega, USA). Both
readouts for were normalized by p24 content of the repli-
cate wells without target cells, and normalized to the
mock condition.
Knockdowns
Cell-to-cell transmission assays with tetraspanin knock-
downs were performed essentially as described above,
with the following differences. HeLa cells were infected
with lentiviruses carrying shRNA at an MOI = 8 2 days
prior to transfection with pNL4-3, and the rest of the assay
was carried out using CEM-Luc target cells as described
above.
When Jurkat cells were used as producers, these were
simultaneously infected with NL4-3 at an approximate
MOI of 0.2 and with lentiviruses carrying shRNA at MOI
= 8. 3 days post-infection, these cells were counted, 0.25
mio cells were mixed with 0.25 mio CEM-Luc target cells,
and co-cultured for 3 days, or cultured without target cells.
The cells were then lysed and assayed for luciferase activity
as above. This readout was normalized by p24 output of
producer cells without target cells to correct for potential
cell death of producer cells due to shRNA treatment.
Latrunculin B treatment
The cell-to-cell transmission assay was carried out as
above, with the following modifications. Producer HeLa
cells were pretreated with Latrunculin B for 1 hour prior to
addition of CEM-GFP target cells. Producer and target
cells were co-cultured in the presence of Latrunculin B for
24 hours, target cells were removed and washed, then cul-
tured for another 24 hours and analyzed by flow cytome-
try.Retrovirology 2009, 6:64 http://www.retrovirology.com/content/6/1/64
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Immunofluorescence microscopy
Jurkat cells were infected with stock NL4-3 virus at an
approximate MOI = 0.1. 48 hours later, cells were allowed
to adhere to Cell-Tak (BD Biosciences) coated coverslips
in Mattek dishes (Mattek Corporation, USA) for 1–2
hours, then fixed and stained with tetraspanin and Gag
antibodies. The following antibodies were used: mouse
anti-CD63, clone H5C6 (Developmental Studies Hybrid-
oma Bank at the University of Iowa), mouse anti-CD81,
clone JS-81 (BD Biosciences), anti-p6 Gag rabbit serum
(gift of Dr. David Ott, NCI Frederick). The cells were then
incubated with appropriate AlexaFluor488 and
AlexaFluor594 secondary antibodies (Invitrogen, USA).
The slides were examined on a Delta Vision Workstation
(DV base 3/3.5, Nikon Eclipse TE200 epifluorescence
microscope fitted with an automated stage, Applied Preci-
sion Inc., Issaquah, WA, USA) and images were captured
in z-series with a CCD digital camera (CoolSnap HQ).
Out of focus light was digitally reassigned using Softworx
deconvolution software (Applied Precision Inc.). Relative
tetraspanin signal intensity was quantified using Volocity
software (Improvision), using the classifier module set to
1 SD below the mean intensity (and no upper limit) to
define the regions of interest, then analyzing their mean
intensity. The background fluorescence intensity was also
determined by selecting an area of a micrograph devoid of
cells, and this value was subtracted from the mean inten-
sity value determined for cells. At least 20 cells were ana-
lyzed for each condition.
Visualization of VS formation
Microscopy experiments were performed essentially as
above, with the following modifications. Uninfected tar-
get Jurkat cells were labeled with CMAC CellTracker Blue
(Invitrogen) according to manufacturer's instructions,
then mixed with an equal number of infected producer
cells. The cell mixture was incubated on Cell-Tak-coated
coverslips for 2 hours at 37°C, then fixed, stained and vis-
ualized as above.
Statistical analyses
A two-tailed, unequal variance Student's t-test was used to
determine significance throughout. A p value less than
0.05 was considered significant.
Results
CD9, CD63 and CD81 are dispensable for HIV-1 budding
Because tetraspanins are known to enhance or repress the
function of peripheral and integral membrane proteins
and because of their well-documented presence at HIV-1
exit sites, we tested if they act as budding co-factors. In
order to achieve efficient silencing of tetraspanins, a lenti-
virus-based shRNA delivery system was employed. Using
this system, at high MOI approximately 99% of the cells
were transduced, and levels of CD63, CD9 and CD81
could be reduced dramatically (see Fig. 1A). Note that
CD63 shows up as a smear on the Western blot, due to
heavy glycosylation of this protein. Production of viral
proteins and particle release in tetraspanin knock-down
cells was compared to protein production and virus shed-
ding in control cells, using Western blot and p24 ELISA
(Figures 1A and 1B). As documented in Fig. 1, all three tet-
raspanins tested were dispensable for HIV-1 assembly and
budding, as ablation of any one or all three of them did
not significantly affect the efficiency of release (p > 0.05).
Consistent with a recent report [33], overexpression of
these three tetraspanins, which augmented their surface
presence 5, 8, and 7 fold for CD9, CD63, and CD81,
respectively, (see [37] for flow cytometry analysis), also
did not affect particle release (Fig. 1C), although we
noticed that CD81 overexpression decreased the synthesis
of viral proteins (data not shown). Because of this varia-
bility in viral output, transmission and infectivity assay
data were always corrected by the amount of virus released
(see Methods).
Overexpression of tetraspanins in HIV-1 producer cells 
reduces the infectivity of cell-free virus as well as cell-to-
cell transmission of virions to target cells
Tetraspanins clearly are enriched in HIV-1 particles (for a
recent review, [16]); yet as shown above, their presence at
the viral exit site is not required for particle formation and
release. We thus set out to test if the virus benefits from the
presence of these membrane proteins once they are incor-
porated into virions. Contrary to our expectation, how-
ever, our initial data (not shown) clearly demonstrated
that this is not the case, and indeed while work for this
report was in progress, a study by Koyanagi and colleagues
showed that overexpression of CD9, CD63, CD81 and
other tetraspanins in virus-producing cells resulted in pro-
duction of virions with considerably reduced infectivity
[33]. As documented in Fig. 2, similar results were
obtained in our system, which we adapted to use the same
set of expression vectors used by the Koyanagi laboratory,
in order to be able to directly compare the two studies.
Thus, HeLa cells were co-transfected with the proviral
expression plasmid pNL4-3 and tetraspanin expression
plasmids. Cell-free supernatants from these producer cells
that contained viral particles (equal amounts of p24 for
each condition, normalized by p24 ELISA) were then used
to infect TZM-bl cells, which contain the beta-galactosi-
dase reporter gene controlled by the HIV LTR [38]. Co-
transfection of HeLa cells with the proviral construct and
with tetraspanin expressors, particularly with a CD63
expressor or with a plasmid that expressed a CD63 which
lacks part of its internalization signal/lysosomal sorting
motif (CD63delL), led to increased levels of tetraspanins
incorporated into released virions (Fig. 2A), and this
markedly reduced the infectivity of the virus (Fig. 2B). In
contrast, co-transfection of a plasmid that expressed L6, aRetrovirology 2009, 6:64 http://www.retrovirology.com/content/6/1/64
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tetraspanin-related protein that is situated within the
same plasma membrane microdomains [39], had no
effect on the infectivity of the viral particles.
Reduced infectivity of cell-free virus may not necessarily
translate into similarly reduced cell-to-cell transmission,
since even particles with reduced affinity for their recep-
tors, for example, may still successfully enter cells if they
are shed into the cleft of the VS (i.e. directly next to the tar-
get cell). We thus sought to determine if the tetraspanin
overexpression also negatively affects the infectivity of the
virus in a cell-to-cell transmission system.
Fig. 3A outlines the assay that was set up to monitor pro-
ductive cell-to-cell transmission of HIV-1. In this system,
HIV-1-producing HeLa cells are co-cultured with indicator
CEM-GFP T lymphocytes, which express GFP under the
control of the HIV LTR [40]. After 24 hours of co-culture,
Tetraspanins are not release factors Figure 1
Tetraspanins are not release factors. HeLa cells were transduced with the indicated shRNA lentiviral vectors at MOI = 8, 
then transfected with pNL4-3 provirus 48 hours post-transduction. 2 days later, cells and viruses were harvested as described 
in Methods, and analyzed by Western blot for CD63, CD9, CD81 and Gag levels (A), or p24 ELISA for p24 CA content (B). 
Normalized percent release was calculated by dividing the amount of p24 released by the total amount of p24 produced (cells 
+ supernatant), then normalizing to the mock-treated sample (set to 100%). Data shown represent the mean of 4 independent 
experiments, +/- standard error of the mean (SEM). (C) HeLa cells were co-transfected with pNL4-3 and the indicated plas-
mids. Cells and viruses were harvested and analyzed by p24 ELISA, as in (B). Data shown represent the mean of 5 independent 
experiments, +/- SEM.
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the target CEM-GFP cells were gently resuspended and
removed, leaving behind adherent producer cells as well
as producer-target syncytia, which were also adherent.
Further, larger cells (potentially syncytia or detached HeLa
cells) were excluded from the read-out of the assay based
on side and forward scatter characteristics during the sub-
sequent flow cytometry analysis. After another 24 hours of
culture, the cells were again resuspended and removed
from the culture flask, again leaving behind any adherent
cells; they were then fixed and analyzed for GFP expres-
sion by flow cytometry. Importantly, we knew that most
of the infection of the reporter cells resulted from their
direct contact with producer cells, because hardly any pro-
ductive infection could be detected if the target cells were
incubated with equivalent amounts of cell-free virus (Fig.
3B). Further, HIV-1-producing HeLa cells formed VS-like
contacts with CEM target cells, and cell-to-cell transmis-
sion could be blocked using Latrunculin B to depolymer-
ize actin, as previously described in the T cell-T cell
scenario [2,3] (see Figures 3C and 3D). Finally, this cell-
to-cell transfer could be almost completely blocked by
adding reverse transcriptase inhibitors (RTIs) AZT and
Efavirenz (EFV) simultaneously with the addition of tar-
get cells (data not shown), demonstrating that reporter
GFP expression was not a result of cell-cell fusion, which
would be insensitive to RTIs, but rather would be the
result of viral integration and productive infection.
As shown in Fig. 3E, using this cell-to-cell transmission
assay, we found that over-expression of CD63 and to a
lesser extent CD9, but not CD81, in producer cells,
reduced productive virus transfer to target cells. The mag-
nitude of the transmission reduction by CD63 overexpres-
sion was roughly half of the effect on cell-free virus
infectivity. As measured for the infectivity of cell-free
virus, overexpression of L6 had no effect on cell-to-cell
virus transfer.
Since HIV-1 accessory proteins Nef and Vpu are well-doc-
umented modulators of viral infectivity and release,
respectively, we also tested if their presence was required
for the suppression of cell-to-cell transfer by CD63 over-
expression. HeLa cells were co-transfected with a CD63
expressor plasmid and either with pNL4-3deltaNef
(NLdelNef) which gives rise to the production of virus
that lacks Nef, or with an HXB2 proviral plasmid, which
leads to the expression of HIV-1 lacking both Nef and
Vpu. Fig. 4 documents that CD63 overexpression sup-
pressed cell-to-cell transmission of both viruses, indicat-
ing that Nef and Vpu are dispensable for the reduced cell-
to-cell transmission caused by this tetraspanin.
Knockdown of CD81 enhances cell-to-cell transmission of 
HIV-1, but not the infectivity of cell-free virus
The results shown in Figures 2 and 3 suggest that tet-
raspanins may play a restrictive role in HIV-1 replication.
We thus hypothesized that knockdown of these host fac-
tors would enhance virion infectivity and cell-to-cell
transmission. However, ablation of CD9, CD63 or CD81
in HIV-1-producing HeLa cells, either alone or pair wise,
or even simultaneous knockdown of all three tet-
raspanins, had no effect on cell-free virus infectivity (Fig.
5A).
To measure cell-to-cell transmission initiated by tet-
raspanin-depleted producer cells, we had to modify the
assay shown in Fig. 3 because the lentiviral system for
shRNA delivery uses GFP as an indicator of transduction.
Instead of CEM-GFP cells, we used CEM.NKR-CCR5-Luc
(CEM-Luc) cells, which express luciferase under the con-
trol of the LTR [41], as targets. Surprisingly, only the
Overexpression of tetraspanins decreases the infectivity of  cell-free virus Figure 2
Overexpression of tetraspanins decreases the infec-
tivity of cell-free virus. (A)HeLa cells were co-transfected 
with pNL4-3 and the indicated plasmids. Released virus was 
pelleted through a 20% sucrose cushion, immunoprecipitated 
using HIVIG and protein A sepharose beads (to purify the 
virus from tetraspanin-bearing exosomes or microvesicles), 
then eluted and analyzed for p24 content by ELISA. Equal 
amounts of p24 were loaded for each sample and analyzed 
for tetraspanin incorporation by Western blot. (B) HeLa cells 
were co-transfected with pNL4-3 and the indicated tet-
raspanin expression plasmids as in (A). Supernatants were 
collected, normalized for p24 content, and the infectivity 
assay was carried out as described in Methods. Data shown 
represent the mean of 5 independent experiments (normal-
ized to vector control) +/- SEM. * denotes a statistically sig-
nificant difference from vector control (p < 0.001).
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knockdown of CD81, but not the ablation of the other tet-
raspanins, enhanced cell-to-cell transmission of HIV-1
(Fig. 5B). However, since this effect was not paralleled by
a significant increase in the entry of cell-free virus into tar-
get cells (p > 0.05), as shown in Fig. 5A, we concluded that
CD81 knockdown in producer cells must affect another
step in cell-to-cell transmission of HIV-1.
Importantly, the lentivirus-based shRNA knockdown sys-
tem allowed us to also assess the effects of tetraspanin
ablation in T cells. Jurkat T lymphocytes were co-infected
with high doses of NL4-3 virus and lentiviruses carrying
shRNA against CD63 and CD81. CD9 knockdown was
not performed, since E6-1 Jurkat cells express very low
amounts of this protein, similar to primary CD4+ T cells
[21]. These producer cells were then co-cultured with
CEM-Luc target cells to allow for cell-to-cell transmission
of virus. As in the HeLa system, knockdown of CD81 was
found to enhance the cell-to-cell transmission of HIV-1
(Fig. 5C), without increasing cell-free virus infectivity
(data not shown). Because this version of the transmis-
sion assay does not allow one to specifically exclude syn-
cytia events, these experiments were also performed in the
presence of EFV, to allow for syncytia formation but not
successful transmission. As in previous experiments, EFV
abolished most of the reporter activity, and the residual
reporter activity did not change significantly in either of
the knockdown conditions (data not shown).
Tetraspanins are downregulated in acutely infected 
lymphocytes
HIV-1 has been well documented to downregulate various
cellular factors that are detrimental to its replication, such
as CD4 or MHC Class I (reviewed e.g. in [42]). Since
CD63, CD9, and CD81 appear to play partially restrictive
roles in HIV-1 replication by reducing the infectivity of
cell-free virions and also by inhibiting cell-to-cell trans-
mission, it seemed plausible that the virus would adapt to
overcome this restriction. Indeed, in cultures of infected
Jurkat lymphocytes lower levels of CD81 could be readily
observed by fluorescence microscopy analysis of newly
infected cells expressing high amounts of Gag (Fig. 6A and
6B). A similar downregulation could be observed by
quantitative Western blot in HIV-1-infected Jurkat cells
Overexpression of CD63 and CD9 inhibits cell-to-cell transmission of HIV-1 Figure 3
Overexpression of CD63 and CD9 inhibits cell-to-cell transmission of HIV-1. (A) A scheme for the cell-to-cell trans-
mission assay. (B) Representative flow cytometry data from the cell-to-cell transmission assay. HeLa cells were transfected or 
not with pNL4-3, then co-cultured with CEM-GFP target cells. Alternatively, cell-free supernatant was collected from producer 
cells and used to infect CEM-GFP cells (free virus). (C) HeLa cells were transfected with HIV-i-GFP (pNL4-3 with MA-GFP, 
green), co-cultured with CMAC-labeled CEM cells (blue), and visualized by fluorescence microscopy. (D) pNL4-3-transfected 
HeLa cells were co-cultured with CEM-GFP targets cells in the presence of the indicated amount of Latrunculin B for 24 hrs. 
Target cells were removed, washed, cultured for another 24 hrs, and then analyzed by flow cytometry. (E) HeLa cells were co-
transfected with pNL4-3 and the indicated tetraspanins. The cell-to-cell transmission assay was carried out as described in 
Methods. Data shown represent the mean of 7 independent experiments (normalized to vector control) +/- SEM. * denotes a 
statistically significant difference from vector control (p < 0.01).
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(Fig. 6C). We also measured similar downregulation of
CD82, another tetraspanin that is abundantly expressed
in T lymphocytes (data not shown), and of CD9 and
CD63, although these were more difficult to analyze, par-
ticularly in Jurkat sub-clones that have low endogenous
levels of these two tetraspanins (data not shown). How-
ever, no tetraspanin downregulation was detected in pro-
virus-transfected HeLa cells (data not shown). Finally,
although the levels of tetraspanins were reduced in HIV-1-
infected T cells, their recruitment to and their concentra-
tion at the VS were still readily detectable (Fig. 6D for
CD81, data not shown for CD9 and CD63), suggesting
that these proteins are not eliminated completely, and
may still carry out certain functions (e.g. cell-cell fusion
prevention, [37]).
Discussion
While tetraspanins have been well-documented to be
involved in various steps of the HIV-1 replication cycle,
until recently only evidence for their functional involve-
ment in potential target cells and in newly infected cells
has been presented. Here, we provide data which establish
tetraspanins also as regulators of HIV-1 spread through
their presence in HIV-1-producing cells.
Despite the enrichment of CD63, CD9 and CD81 at HIV-
1 budding sites, their knockdown did not affect the effi-
ciency of HIV-1 release from HeLa cells. This suggests that
these proteins do not act as budding factors for HIV-1,
although we cannot formally exclude the possibility of
compensation by other functionally redundant tet-
raspanins (e.g. CD82, CD151, etc). These results are in
line with findings of the Marsh group, who reported that
knockdown of CD63 in macrophages did not alter the
efficiency of viral release, regardless of whether the knock-
down was done prior to or before infection [30], though
another recent study reported that CD63 knockdown after
HIV-1 infection of macrophages reduced the amount of
virus released from these cells [28]. However, in the latter
study, it remained unclear exactly which step was inhib-
ited by CD63 ablation, as the amounts of released parti-
cles apparently were not corrected by the levels of cell-
associated viral proteins. Further, another recent study uti-
lizing a chronically infected T-cell line reported that
knockdown of CD81 or treatment with an anti-CD81
antibody reduced viral release [29]. It is possible that this
effect may be dependent on the cell type, and the poten-
tial release functions of tetraspanins may not be recapitu-
lated in the HeLa cell system.
Overexpression of CD63, CD9 and CD81 repressed cell-
free virus infectivity. Similar data were recently published
by Koyanagi and colleagues [33], although in our study
the magnitude of the repression appears to vary more
between different tetraspanins, the most potent being
CD63. However, while it seems likely that specific tet-
raspanins act differently, we cannot exclude that this effect
simply depends on endogenous levels of the tetraspanin
at the surface in producer cells, with CD63 displaying the
lowest surface fraction of the tetraspanins analyzed in the
Nef and Vpu are not required for inhibition of cell-to-cell transmission by CD63 Figure 4
Nef and Vpu are not required for inhibition of cell-to-cell transmission by CD63. HeLa cells were co-transfected 
with the indicated proviral plasmid and either with pCD63 or empty vector. Cell-to-cell transmission assay was carried out as 
described in Methods. Data shown represent the mean of 3 independent experiments (normalized to vector control for each 
virus) +/- SEM. * denotes a statistically significant difference from vector control (p < 0.01).
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Knockdown of CD81 enhances cell-to-cell transmission, but not cell-free infectivity Figure 5
Knockdown of CD81 enhances cell-to-cell transmission, but not cell-free infectivity. HeLa cells were infected with 
the indicated shRNA-carrying lentiviruses and transfected with pNL4-3. (A) Cell-free infectivity. Data shown represent the 
mean of 7 independent experiments (normalized to vector control) +/- SEM. (B) Cell-to-cell transmission. Data shown repre-
sent the mean of 4 independent experiments (normalized to vector control) +/- SEM. (C) Jurkat T cells were co-infected with 
shRNA-carrying lentiviruses and NL4-3. Data shown represent the mean of 4 independent experiments (normalized to vector 
control) +/- SEM. Cell-to-cell transmission was carried out as described in Methods. * denotes a statistically significant differ-
ence from scrambled shRNA (p < 0.05).
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cells used in our analysis. Koyanagi and colleagues also
showed that the inhibition of infectivity was not due to
altered Gag or Env processing or Env incorporation, and
occurred specifically at the virus-cell fusion stage of entry.
Consistent with the latter finding, we observed that cell-
cell fusion driven by Env is also inhibited by tetraspanin
overexpression [37].
As shown in Fig. 3, overexpression of CD63, and to a
lesser extent of CD9, also inhibited cell-to-cell transmis-
sion of HIV-1, suggesting that reduced infectivity of virus
is capable of reducing its cell-to-cell transmission. The
magnitude of this repression was about half of the effect
on cell-free infectivity, thus the effects on cell-free infectiv-
ity are not exactly matched in cell-to-cell transmission. It
is quite possible that tetraspanin overexpression, in addi-
tion to suppressing infectivity, could also have other,
potentially positive effects on transmission, e.g. prevent-
ing fusion of target and producer cells, and thus preserv-
ing productive VSs [37]. We have measured syncytia
CD81 is downregulated in acutely infected lymphocytes Figure 6
CD81 is downregulated in acutely infected lymphocytes. Jurkat T lymphocytes were infected with NL4-3, then fixed 
and stained for Gag and CD81. (A) A representative image of CD81 labeling in infected Jurkat cells. A single Z-section is 
shown. Scale bar represents 10 μm. (B) Quantification of immuno-fluorescence labeling of CD81 in infected (Gag+) and unin-
fected (Gag-) cells. Data shown represent the mean +/- SEM. * denotes a statistically significant difference from uninfected cells 
(p < 0.05). See Methods for more details. (C) Jurkat cells were infected with NL4-3. 4 days post-infection, when the percentage 
of infected cells was above 50%, cells were lysed, and CD81 and GAPDH protein levels were analyzed by Western blot. (D) 
Recruitment of CD81 to the VS in acutely infected Jurkat cells. Target Jurkat cells were labeled with CMAC Cell-tracker (blue) 
and co-cultured with NL4-3-infected producer Jurkat cells for 2 hours on PLL-coated coverslips. The cells were then fixed and 
stained for the indicated antigens as described in Methods. A single Z-section is shown. Maximum and minimum intensity of 
each wavelength were adjusted in order to highlight the areas with the most intense signal. Scale bars represent 10 μm.
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formation directly in our cell-to-cell transmission assay
and found that while overexpression of CD63 repressed
syncytia formation and transmission with similar effi-
ciency, syncytia formation was relatively rare, occurring
approximately once per 10 successful transmission events
(data not shown), explaining why no obvious positive
effect of syncytia repression was observed in our assays.
Interestingly, overexpression of a different tetraspanin,
CD82, was also shown to inhibit cell-to-cell transmission
of another human retrovirus, HTLV-I, while also inhibit-
ing syncytia formation [43]. CD82 and CD81 were found
to associate with HTLV-I Env and/or Gag protein, suggest-
ing that tetraspanins are part of a common pathway of
fusion and transmission regulation for different retrovi-
ruses [43-45].
The fact that knockdown of CD63, CD9 and CD81 failed
to increase cell-free infectivity, although in agreement
with previously published data [30,33], is surprising,
given that overexpression of these proteins reduced infec-
tivity considerably. The most parsimonious explanation
for this finding may be that the endogenous levels of these
proteins in producer HeLa cells or acutely infected T cells
are too low to effectively suppress infectivity. In fact, we
have observed that uninfected lymphocytes have a rela-
tively higher surface density of some tetraspanins, such as
CD81 and CD82 (data not shown), and this may explain
why the virus would downregulate these proteins to a
level that is optimal for its infectivity, and yet is not too
low to prevent syncytia formation (discussed in more
detail below). Consistent with this, we have observed that
virus-producing HeLa cells do not exhibit any appreciable
tetraspanin downregulation (data not shown). Also,
downregulation of tetraspanins in producer HeLa cells
does in fact enhance syncytia formation [37]. Finally,
Muriaux and colleagues reported that CD81 knockdown
in chronically infected T cells reduced infectivity of
released virus [29]. As above, we speculate that the levels
of CD81 (and other tetraspanins) in these cells are higher
than in HeLa cells or acutely infected or activated T cells,
and this is supported by the findings of Koyanagi and col-
leagues [33].
Also consistent with the idea that the levels of CD9 and
CD63 in HeLa cells are relatively low, downregulation of
these two tetraspanins does not alter cell-to-cell transmis-
sion of HIV-1. Intriguingly though, knockdown of CD81
enhanced cell-to-cell virus transmission without affecting
infectivity. This suggests that CD81 may play a role at a
different step in the transmission process. Since this tet-
raspanin has been shown to be involved in cell-cell adhe-
sion and cell migration, in addition to cell-cell fusion, it is
possible that it affects the frequency or the duration of VS
formation. Future studies will help to dissect exactly
which step CD81 is involved in.
We found that tetraspanins are downregulated in infected
lymphocytes, suggesting that HIV-1 may be actively low-
ering the levels of these proteins. This is in disagreement
with data published by Sattentau and colleagues, who did
not find a difference in CD63, CD9 and CD81 levels
between infected and non-infected lymphocytes [21].
However, in the aforementioned study, viral proteins
were not directly measured together with tetraspanin lev-
els. In our experiments, we observed that tetraspanin
expression was quite variable in infected cultures, and
clear-cut downregulation was only observed in cells
expressing relatively high levels of Gag. Interestingly, a
similar downregulation of tetraspanins was observed in
PHA/PMA-stimulated lymphocytes chronically infected
with HIV-1, which also correlated with increased virus
production and enhanced virion infectivity [33]. Intrigu-
ingly, enhancement of virion infectivity by HIV-1 Nef in
CD4-negative cells has been recently shown to be depend-
ent on the clathrin/dynamin2-dependent pathway [46]. It
is tempting to speculate that HIV-1 Nef may be involved
in downregulating tetraspanins from the plasma mem-
brane, preventing their incorporation into virions and
thus enhancing virion infectivity. Another possibility is
that tetraspanins are simply shed in the released virions,
as a consequence of their incorporation into virus parti-
cles, although experiments performed in our laboratory
indicate that tetraspanin downregulation does not corre-
late with the amount of released virus (M.L., D.K. and
M.T., unpublished data).
Conclusion
Overall then, are tetraspanins restriction factors for HIV-
1? Given that tetraspanins appear to reduce virus infectiv-
ity and cell-to-cell transmission, and that the virus down-
regulates these proteins, it is tempting to speculate that
they indeed hinder HIV-1 replication. However, since tet-
raspanins also play a positive role, by preventing syncytia
formation [37], and thus likely preserving the VS, it seems
likely that the most beneficial scenario for the virus is to
achieve a balance between enhanced infectivity and low
syncytia formation. Consistent with this, we observed
only a partial downregulation of tetraspanins in infected
cells, and tetraspanins were still recruited to the VS
(although at presumably lower levels, hence allowing for
the enhancement of infectivity), where they could prevent
cell-cell fusion. Further, while our current cell-to-cell
transmission assays indicate a restrictive role for tet-
raspanins, this may not be the case in vivo, where fusion
prevention may potentially be more important than infec-
tivity enhancement. As discussed above, in our transmis-
sion assay, syncytia formation is a relatively rare event,
occurring in roughly once per 10 successful transmission
events (using HeLa cells as producers); thus a reduction in
syncytia formation (e.g. by tetraspanin overexpression)
would result in a very modest transmission enhancement.Retrovirology 2009, 6:64 http://www.retrovirology.com/content/6/1/64
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In vivo however, e.g. when the virus replicates in lymph
nodes, where the cells are much more densely packed,
there is less opportunity for producer and target cells to
separate after VS formation and virus transmission, and
the effects of impaired fusion regulation, if quantifiable,
might become evident. Finally, another limitation of our
transmission assays is that they measure the effect of tet-
raspanins on a single transmission step. However, multi-
step transmission assays (e.g. a spreading infection in a
lymphocyte culture), become very difficult to interpret,
because tetraspanins, as mentioned before, also play a
role in target cells.
Altogether, our results provide evidence for an active role
of tetraspanins in cell-to-cell transmission of HIV-1, a
process that may be crucial for virus spread in vivo and one
which is only beginning to be understood. Because indi-
vidual tetraspanins are not essential for host cell survival,
they may provide an avenue for therapeutic intervention
with the virus life cycle.
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